In vitro diagnostics company Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced on Monday that the US Food and Drug Administration granted 510(k) clearance for its Accelerate Arc system and BC kit.
This platform automates positive blood culture sample preparation for use with Bruker's MALDI Biotyper CA System and Sepsityper software.
Designed for clinical labs, the system streamlines microbial identification, bypassing the need for overnight culture methods. This reduces wait times for results, crucial in sepsis treatment. Accelerate Arc leverages Bruker's reference library for rapid identification, complementing the company's future WAVE system for antibiotic susceptibility testing.
Faster results improve patient outcomes, lower antimicrobial resistance and reduce hospital costs. Additionally, Accelerate Arc replaces overnight subculture and labour-intensive Laboratory Developed Tests, meeting regulatory pressures for FDA-cleared devices.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition